Cord Blood Amer Inc. (WKN: A0EAGC / CBAI) / OTCBB

Cord Blood America Continues International Expansion




 

 
-- Company Enters Lucrative Markets of Panama, Bermuda and Aruba with Marketing Partner --


SANTA MONICA, Calif., June 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which earlier this month announced sales operation expansion into the European Union, said today it has signed an agreement with a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba. The marketing arrangement is expected to target hospitals and obstetricians/gynecologists in those areas. Cord Blood will receive revenue from the sale of cord blood processing and storage services sold to each family. Marketing of such services will commence immediately.


"We are excited to begin marketing our cord blood processing and storage services in areas where we have the first-mover advantage," said founder and CEO Matthew Schissler. "We will be the first party offering such services in Bermuda and Aruba, and the second party in Panama. Based upon the experience in North America, we believe that being first in the market will provide us with compelling advantages. We see the storage of stem cells internationally as potentially very profitable. While the size of these overall countries is relatively small, given the highly attractive demographics of their population we believe the opportunities could be lucrative. The advantages of storing stem cells at birth, and at other times in life, are becoming well known worldwide."


Panama, with a population of 3.3 million, has become an international business center in Central America, with a fast growing economy and the highest per capita consumer spending in the region. Aruba, an affluent island in the southern Caribbean, is overseen by the Netherlands, while Bermuda, a British territory in the North Atlantic, has previously had the world's highest GDP per capita.


Quelle: http://news.prnewswire.com/.../story/06-22-2009/0005047601&EDATE=

In a press release out on Jun 22, 2009 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which earlier this month announced sales operation expansion into the European Union, said today it has signed an agreement with a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba. The marketing arrangement is expected to target hospitals and obstetricians/gynecologists in those areas. Cord Blood will receive revenue from the sale of cord blood processing and storage services sold to each family. Marketing of such services will commence immediately.

Quelle: http://www.tradingmarkets.com/.site/news/Stock%20News/2383801/

Übersetzungshilfe: http://translate.google.de/translate_t#

ich hoffe, hier passiert bald mal wieder etwas positives (am Kurs) - allein so recht glauben kann ich es nicht mehr...

Technisch/taktisch mMn : Geld futsch!

....einfach einige in Depot legen und abwarten. Meine Meinung.

Cord Blood America inc. (CBAI.OB: 0.0044 0.00%) shares jumped more than 20 percent following Monday’s announcement that it was continuing to expand internationally. Specifically, the company has been expanding its sales operations in the European Union and signed a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba.

Quelle: http://theotcinvestor.com/...otc-bb-and-pinksheets-market-movers-304/

Übersetzungshilfe: http://translate.google.de/translate_t#

........für eine innovative Geldanlage mit Zukunft!

Cord Blood America Hires Management Team for Its New Stem Cell Laboratory

 

SANTA MONICA, Calif. and LAS VEGAS, July 10 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today it has hired famed Immunologist Dr. Geoffrey John O'Neill as its new Laboratory Director and Brian Pockett as Vice President of Laboratory Operations.


Cord Blood America recently announced it is opening a state-of-the-art laboratory for the storage of multiple stem cell products, including umbilical cord blood stem cells, in Las Vegas, Nevada.


"We are pleased that two such distinguished, experienced, successful professionals will be overseeing our new lab," said Company founder and CEO Matthew Schissler. "The lab will be used to process and store umbilical cord blood stem cells, to store other forms of stem cells such as peripheral blood stem cell and adipose tissues, and for research and product development."


Dr. O'Neill was Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida and was Laboratory Director for the Bio-Matrix Scientific Group Inc., a San Diego biotech research and development firm in the stem cell sector. He received a Ph.D. in Immunology from the University of Glasgow, Scotland, and is the author or co-author of more than 75 publications in his field in which he has won a number of significant honors.


Mr. Pockett has more than 30 years professional experience in operations, business development, marketing, sales and financial and grant development. He has served as a consultant on global distribution, product development, commercialization, investment and intellectual properties for some of the largest companies in the U.S. He also served as Managing Director and Chief Operating Officer for Bio-Matrix Scientific Group Inc.


http://news.prnewswire.com/.../story/07-10-2009/0005057738&EDATE=  

.........sehr innovative Firma mit internationalen Ambitionen die sich langfristig auszahlen werden!

......werde meine Stücke auch noch ein wenig aufstocken !

ANPI, Taxus FDA approval
http://www.streetinsider.com/FDA/...t+Liberte+Long+Stent/4799287.html  

........nach oben drin für den Kurs. Äußerst innovatives Unternehmen mit internationalen Ambitionen.

PSAR Trigger...Freitags verkäufer raus ?? :-)

 

 

Cord Blood America Highlights Significant 2009 Progress




 

 



SANTA MONICA, Calif. and LAS VEGAS, July 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today said its accomplishments in the first half of 2009 are the most significant in the Company's history and Cord Blood America is progressing to its goal of being the most important company in stem cell storage in the world.


January 6 - Launched the first social media campaign in the industry to start a public conversation about the potential usefulness of stem cells and the importance of storing umbilical cord blood stem cells.
January 9 - Established its three pillars of success for 2009: Organic growth, acquisitions and debt reduction leading to a healthy balance sheet.
February 9 - The Obama Administration announces its plan and support of stem cell research in the United States; Cord Blood America is listed on the ETF Innovators Stem Cell 40 company index.
February 12 - CBAI announces $1 million reduction in long term debt.
February 25 - CBAI announces restructuring of long term debt to free up cash flow for the company.
March 5 - CBAI noted as the top stock performer on ETF Innovators Stem Cell index, with a year-to-date stock price increase of 279 percent.
April 5 - Congress introduces legislation to promote Family Banking of Umbilical Cord Blood stem cells; CBAI announces its total long term debt reduction at $1.75 million.
April 9 - CBAI announces its first customer in Germany, noting its dedication to organic growth.
April 23 - CBAI announces additional debt reduction of $817,000.
May 7 - CBAI says it will acquire or build its own stem cell processing and storage laboratory, eliminating the need to outsource lab services and projecting a significant increase in gross profit once complete.
May 14 - CBAI announces it received a $2.3 million commitment to finance the building of its stem cell lab.
May 27 - CBAI announces debt has been reduced by $4.194 million in 2009.
June 11- CBAI announces additional expansion in Europe.
June 22 - CBAI announces contracting independent affiliate to sell services in Caribbean and Central America.



Since the end of the mid-point of 2009, Cord Blood America has further secured $7.5 million in long term equity financing for growth and acquisition opportunities; announced it has begun building the one of the largest stem cell labs in the U.S.; and announced hiring of an experienced, successful management team to manage its new laboratory


"On January 6, 2009, the closing CBAI stock price was $0.0017. On July 10, 2009, the closing stock price was 0.0033, a 94% increase in 6 months of trading. That's not where we want to be, we are still very undervalued, and I understand that the day-to-day swings of our very liquid and volatile stock price cause some investor concern," said Matthew Schissler, Chairman and CEO. "I tell investors to take a snapshot of the last six months, not six hours. Micro cap stocks are perhaps not for the faint of heart. We believe we're building a very valuable company and this snapshot of the past six months shows our progress."


"In January, CBAI stated its mission is to lay the foundation for a much stronger healthier company by the end of 2009, which included organic growth, acquisition and debt reduction. As you can see by these highlights, we remain laser-focused on executing these strategies," Mr. Schissler said. "Because of our focus, we were able to raise significant funding to build a lab with the future growth opportunities it affords us. We are also pleased by the current support of stem cell research in Washington, D.C. and Congressional and state legislative focus on family stem cell banking legislation."


About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.


Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.


Quelle: http://news.prnewswire.com/.../story/07-20-2009/0005062336&EDATE=

Übersetzungshilfe: http://translate.google.de/translate_t#

Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview




 

 


SANTA MONICA, Calif. and LAS VEGAS, July 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that its founder and CEO Matthew Schissler was featured on Monday in a television interview on KVVU Fox News Las Vegas, in which he discusses the 17,000 square foot facility in Las Vegas, Nevada that it recently leased to develop a state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells.


"Since we announced earlier this month that we had leased the Facility, there has been tremendous interest from parties in the Western United States in discussing opportunities to partner with the Company," said Mr. Schissler. "In addition to our current cord blood stem cell business, we are excited about having the capability to process and store multiple forms of stem cells, and expect to begin generating different revenue streams from the sale of these services in early 2010."

The entire interview is available at www.cordblood-america.com.

Quelle + Volltext: http://news.prnewswire.com/.../story/07-22-2009/0005064444&EDATE=

Übersetzungshilfe: http://translate.google.de/translate_t#

Durch den Regierungswechsel in den USA und die damit verbunde Förderung, wie z.B. der Stammzellenforschung, wird Cord Blood außergwöhnlich provitieren. Die Berichte der letzten Monate bestätigen dies. Es ist in absehbarer Zeit damit zu rechnen, dass Cord Blood enorme Gewinne einfahren wird. Der Aktienkurs wird dann explodieren.

 

hoffe wir haben den boden gesehen.

lg speku  

.......na mal sehen !

 

Cord Blood - das Zukunftsunternehmen !

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.


Click here to view social media version of this release.


Click here to visit the Cord Blood America Social Media Newsroom.


Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Quelle: http://news.prnewswire.com/.../story/07-22-2009/0005064444&EDATE=

Übersetzungshilfe: http://translate.google.de/translate_t#

Cord Blood America Inc. (OTCBB: CBAI | Quote | Chart | News | PowerRating) through its subsidiaries, provides private cord blood stem cell preservation services to families in the United States. It also engages in collecting, processing, and preserving peripheral blood and adipose tissue stem cells, which allows individuals to privately preserve their stem cells for potential future use in stem cell therapy. In addition, the company engages in the collection, transportation, testing, and preservation of umbilical cord blood. Further, it creates direct response television and radio advertising campaigns, including media placement and commercial production; involves in the placement of advertising in television and radio outlets; and production of advertising content, including television commercials and radio copy. Additionally, the company engages in procuring and setting up call centers; editing, dubbing, and distribution of radio and television commercials; and procuring and placing print advertising, as well as provides advertising and marketing consulting services relating to the customer''s marketing campaign. The company is headquartered in Santa Monica, California. With 1.58 billion shares outstanding and 67,300 shares declared short as of June 2009, there is no longer a failure to deliver in shares of CBAI. According to quarterly data provided by the SEC, there were still 4,342,860 shares of CBAI that were failing-to-deliver as of September 18, 2007.

Quelle: http://www.tradingmarkets.com/.site/news/Stock%20News/2438494/

Übersetzungshilfe: http://translate.google.de/translate_t#

;-)

wär hätte da schon was gegen ?

lg speku

auf einen günen freitag  

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39892815
http://www.skymarkresearch.com/cbai.pdf